TaiMed Biologics Inc. reported earnings results for the third quarter and nine months ended September 30, 2023. For the third quarter, the company reported sales was TWD 157.55 million compared to TWD 96.58 million a year ago. Net loss was TWD 5.88 million compared to TWD 35.98 million a year ago. Basic loss per share from continuing operations was TWD 0.02 compared to TWD 0.14 a year ago. Diluted loss per share from continuing operations was TWD 0.02 compared to TWD 0.14 a year ago.
For the nine months, sales was TWD 333.56 million compared to TWD 236.54 million a year ago. Net loss was TWD 134.52 million compared to TWD 231.51 million a year ago. Basic loss per share from continuing operations was TWD 0.53 compared to TWD 0.92 a year ago. Diluted loss per share from continuing operations was TWD 0.53 compared to TWD 0.92 a year ago.